India's Biosimilar Norms: Patient Safety Debate Boils Over

A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.

More from Biosimilars

More from Biosimilars & Generics